Comparing Delayed versus Simultaneous Bone Marrow Transplantation to Achieve Lung Allograft Tolerance in Non-Human Primates
Purpose: Long-term, immunosuppression-free survival of haplo-matched lung allografts has been achieved in non-human primates (NHPs) using a delayed mixed-chimerism protocol. Previous work in kidney and heart transplantation suggest that the timing of donor bone marrow transplant (BMT) is critical for tolerance induction. We investigated whether simultaneous versus delayed BMT generates a more effective protocol for inducing tolerance of mismatched lung allografts. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Nawalaniec, J. O, A. Dehnadi, N. Hays, J. Muoio, C. Winter, I. Hanekamp, J. Madsen, J.S. Allan Source Type: research
GSE262427 Macrophage WEE1 promotes atherosclerosis via directly phosphorylating NF- κB p65 subunit and inducing inflammatory response
Conclusions: Our findings demonstrated that macrophage WEE1 promotes inflammatory atherosclerosis by directly binding to p65 and phosphorylate it at S536. This study provides WEE1 as a new p65 regulator in inflammation and a potential therape utic target for atherosclerosis. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - March 30, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus Source Type: research
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation, Published online: 30 March 2024; doi:10.1038/s41409-024-02275-6Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 30, 2024 Category: Hematology Authors: Enrico Maffini Myriam Labopin Nicolaus Kr öger J ürgen Finke Matthias Stelljes Thomas Schroeder Herman Einsele Johanna Tischer Martin Bornh äuser Wolfgang Bethge Arne Brecht Wolf R ösler Peter Dreger Kerstin Sch äfer-Eckart Jakob Passweg Igor Wolfgan Source Type: research
Could bone marrow transplants transmit Alzheimer's disease?
The mainstream view is that Alzheimer ' s starts in the brain, but researchers were able to transfer the condition in mice by injections of bone marrow (Source: New Scientist - Health)
Source: New Scientist - Health - March 28, 2024 Category: Consumer Health News Source Type: research
Bone marrow transplants spread Alzheimer ’s-like disease in mice, controversial study reports
Bone marrow transplants between mice can transmit symptoms and pathology associated with Alzheimer’s disease, according to a controversial study published today in
Stem Cell Reports
. Its authors found that healthy mice injected with marrow from a mouse strain carrying an extremely rare, Alzheimer’s-linked genetic mutation later developed cognitive problems and abnormal clumping of proteins in the brain.
In claims that other scientists in the field have criticized as overstated, the team says its findings demonstrate “Alzheimer’s disease transmission” and support screening of human bone mar...
Source: Science of Aging Knowledge Environment - March 28, 2024 Category: Geriatrics Source Type: research
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
Bone Marrow Transplantation, Published online: 27 March 2024; doi:10.1038/s41409-023-02195-xA phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Ray Mun Koo Eric Wong Joanne E. Davis Travis Perera Andrew Lim Rachel M. Koldej David S. Ritchie Source Type: research
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, Published online: 23 March 2024; doi:10.1038/s41409-024-02270-xEASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 23, 2024 Category: Hematology Authors: Carles Tolosa-Ridao Enric Cascos Luis Gerardo Rodr íguez-Lobato Alexandra Pedraza Mar ía Suárez-Lledó Paola Charry Mar ía Teresa Solano Julia Martinez-Sanchez Joan Cid Miquel Lozano Laura Rosi ñol Jordi Esteve Álvaro Urbano-Ispizua Francesc Fern á Source Type: research
Improving the EASIX’ predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, Published online: 23 March 2024; doi:10.1038/s41409-024-02267-6Improving the EASIX’ predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 23, 2024 Category: Hematology Authors: Silvia Escribano-Serrat Luis Gerardo Rodr íguez-Lobato Mar ía Suárez-Lledó Alexandra Pedraza Paola Charry Joan Cid Miquel Lozano Jordi Esteve Laura Rosi ñol Francesc Fern ández-Avilés Enric Carreras Maribel D íaz-Ricart Carmen Mart ínez Montserra Source Type: research
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation, Published online: 21 March 2024; doi:10.1038/s41409-024-02268-5Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 21, 2024 Category: Hematology Authors: Sara Villar Sylvie Chevret Xavier Poire Magalie Joris Patrice Chevallier Jean-Henri Bourhis Edouard Forcade Sylvain Chantepie David Beauvais Nicole Raus Jacques-Olivier Bay Michael Loschi Raynier Devillier Remy Dul éry Patrice Ceballos Marie Th érèse R Source Type: research
Storage of wine and blood
Bone Marrow Transplantation, Published online: 21 March 2024; doi:10.1038/s41409-024-02262-xStorage of wine and blood (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 21, 2024 Category: Hematology Authors: Shaun R. McCann Source Type: research
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial
Bone Marrow Transplantation, Published online: 20 March 2024; doi:10.1038/s41409-024-02271-wImproving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 20, 2024 Category: Hematology Authors: Sophie Estran Michael Loschi Sami Benachour Aliz ée Soldati Edmond Chiche Rinzine Sammut Guillaume Robert Arnaud Jacquel Jacques Chibois Stephane Schneider Thomas Cluzeau Source Type: research
Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation, Published online: 19 March 2024; doi:10.1038/s41409-024-02256-9Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - March 19, 2024 Category: Hematology Authors: Romain Gui èze Diderik-Jan Eikema Linda Koster Johannes Schetelig Henrik Sengeloev Jakob Passweg J ürgen Finke Mutlu Arat Annoek E. C. Broers Friedrich St ölzel Jenny Byrne Cristina Castilla-Llorente Peter Dreger Matthias Eder Tobias Gedde-Dahl Nicolau Source Type: research
Cellular senescence promotes meibomian gland dysfunction in a chronic graft-versus-host disease mouse model
CONCLUSIONS: Cellular senescence, along with expression of SASP factors, exhibited increased activity in the eyelids, particularly in the MGs of cGVHD mice. ABT-263 mitigated the severity of MGD. These findings highlight the potential of targeting cellular senescence as an effective approach for MGD treatment in cGVHD.PMID:38499288 | DOI:10.1016/j.jtos.2024.03.006 (Source: The Ocular Surface)
Source: The Ocular Surface - March 18, 2024 Category: Opthalmology Authors: Shinri Sato Yoko Ogawa Eisuke Shimizu Kazuki Asai Takahiro Okazaki Robert Rusch Masatoshi Hirayama Shigeto Shimmura Kazuno Negishi Kazuo Tsubota Source Type: research
Cellular senescence promotes meibomian gland dysfunction in a chronic graft-versus-host disease mouse model
CONCLUSIONS: Cellular senescence, along with expression of SASP factors, exhibited increased activity in the eyelids, particularly in the MGs of cGVHD mice. ABT-263 mitigated the severity of MGD. These findings highlight the potential of targeting cellular senescence as an effective approach for MGD treatment in cGVHD.PMID:38499288 | DOI:10.1016/j.jtos.2024.03.006 (Source: The Ocular Surface)
Source: The Ocular Surface - March 18, 2024 Category: Opthalmology Authors: Shinri Sato Yoko Ogawa Eisuke Shimizu Kazuki Asai Takahiro Okazaki Robert Rusch Masatoshi Hirayama Shigeto Shimmura Kazuno Negishi Kazuo Tsubota Source Type: research
SOHO State of the Art Updates and Next Questions | An Update on Higher Risk Myelodysplastic Syndromes
High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML) and therapeutic need for bone marrow transplantation. Use of blast percentage and other morphologic features to define MDS subtypes is rapidly shifting to incorporate genetics, resulting in a subset of former HR-MDS patients now being considered as AML in presence of leukemia-defining genetic alterations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Source Type: research
